In September 2003, the U.S. Food and Drug Administration (FDA) ordered Eli Lilly to revise the Zyprexa labeling and product information to inform doctors and patients that the use of Zyprexa (and other SGAs) has been associated with an increased risk of glucose abnormalities and diabetes. On March 1, 2004, Eli Lilly issued a “Dear Doctor” letter to individual physicians in which it informed doctors of the increased risk of hyperglycemia and diabetes in patients taking Zyprexa and described the label changes.